|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
|
MAPLIGHT THERAPEUTICS, INC. (Name of Issuer) |
Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) |
(CUSIP Number) |
Barbara Fiorini Novo Holdings A/S, Tuborg Havnevej 19, Hellerup, G7, DK-2900 45 3527 6592 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
07/30/2026 (Date of Event Which Requires Filing of This Statement) |
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
Novo Holdings A/S | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF, WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DENMARK
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
2,086,622.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
4.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
CO |
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Voting Common Stock, par value $0.0001 per share | |
| (b) | Name of Issuer:
MAPLIGHT THERAPEUTICS, INC. | |
| (c) | Address of Issuer's Principal Executive Offices:
800 Chesapeake Drive, Redwood City,
CALIFORNIA
, 94063. | |
Item 1 Comment:
This Amendment No. 1 (this "Amendment No. 1" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on November 4, 2025 (the "Statement") by the Reporting Persons. Unless otherwise defined herein, capitalized terms used in this Amendment No. 1 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | Novo Holdings A/S beneficially owns 2,086,622 shares of common stock representing approximately 4.9% of the Issuer's outstanding shares of common stock (the "Novo Shares"), based upon 42,618,165 shares of common stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.
| |
| (b) | Novo Holdings A/S is a Danish corporation wholly owned by the Foundation. Novo Holdings A/S has the sole power to vote and dispose of the Novo Shares. Neither the Foundation nor any person listed on Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares. | |
| (c) | Except as set forth below, Novo Holdings A/S has not effected any transactions with respect to the Issuer's common stock during the past sixty days and neither the Foundation nor any person listed on Schedule I has effected any transactions in the Issuer's Common Stock within the past 60 days.
On July 30, 2026, Novo Holdings A/S sold the following shares in open market transactions:
- 1,314,195 shares of common stock in a single transaction at a price of $12.00 per share;
- 220,723 shares of common stock at prices ranging from $13.55 to $14.54 per share (a weighted-average price of $14.19 per share); and
- 65,082 shares of common stock at prices ranging from $14.55 to $15.00 per share (a weighted-average price of $14.69 per share).
| |
| (d) | Novo Holdings A/S does not know of any other person having the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Novo Shares. | |
| (e) | The Reporting Persons ceased to be the beneficial owners of more than five percent of the common stock on July 30, 2026. | |
| Item 7. | Material to be Filed as Exhibits. | |
Exhibit 99.1 Schedule I | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|